Moody's gives Takeda top-notch rating

Moody's Investory Services gave a thumbs up to Takeda Pharmaceuticals, with an "Aa1" issuer rating, saying the company's outlook is stable and it is likely to remain strong financially following the its acquisition of Millennium Pharmaceuticals for $7.4 billion. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.